Iron Metabolism: An Emerging Therapeutic Target in Critical Illness
- PMID: 30850005
- PMCID: PMC6408790
- DOI: 10.1186/s13054-019-2373-1
Iron Metabolism: An Emerging Therapeutic Target in Critical Illness
Abstract
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2019. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2019 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
Edward Litton was the principle investigator of the IRONMAN study that received in-kind support of study drug from Vifor Pharma. The authors declare no other conflicts of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Comment in
-
Hepcidin is described as the master regulator of iron: could its removal by CRRT lead to iron dysmetabolism in the critically ill?Crit Care. 2020 Sep 22;24(1):570. doi: 10.1186/s13054-020-03295-6. Crit Care. 2020. PMID: 32962732 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical